logo
What to do if you have measles - symptoms and when to call for a doctor or 999

What to do if you have measles - symptoms and when to call for a doctor or 999

Yahoo7 days ago
Measles can cause serious issues among some people, and it's known to spread 'very easily', so here is everything you need to know.
The infection can be prevented by having the MMR vaccine, but if you do get measles, it's worth knowing the symptoms to look out for, when you need to call for medical help and how to avoid spreading it further.
The NHS website explains: 'Measles usually starts with cold-like symptoms, followed by a rash a few days later. Some people may also get small spots in their mouth.'
Cold-like symptoms can include a high temperature, a runny or blocked nose, sneezing, a cough or red, sore and watery eyes.
Measles cases are rising in England. You can still ask your GP practice for the MMR vaccine if your child has missed either of these 2 doses. For more info ➡️ https://t.co/pGbmMXqcSf pic.twitter.com/bRcJYSzvqb
— NHS (@NHSuk) January 19, 2024
You might start to notice small white spots in the mouth, including inside the cheeks and on the back of the lips. It's not unusual for these spots to last for a few days.
Once you've had the cold-like symptoms for a few days, you will probably start to develop a rash, which usually starts on the face and behind the ears. It then spreads to the rest of the body, the NHS explains.
The rash isn't usually itchy, and sometimes the measles rash can be raised and join other parts to make blotchy patches.
On white skin, the rash often looks red or brown, but it can sometimes be harder to see on black or brown skin.
The NHS adds: 'It's very unlikely to be measles if you've had both doses of the MMR vaccine or you've had measles before.'
The NHS outlines when you should ask for an urgent GP appointment or call 111, including if:
you think you or your child may have measles
your child is under 1 year old and has come into contact with someone who has measles
you've been in close contact with someone who has measles and you're pregnant or have a weakened immune system
you or your child have a high temperature that has not come down after taking paracetamol or ibuprofen
you or your child have difficulty breathing – you may feel more short of breath than usual
your baby or young child is not feeding well, or taking less feeds or fluids than usual
you or your child are weeing less than usual (or your baby has fewer wet nappies)
you or your child feels very unwell, or you're worried something is seriously wrong
The health service added: 'Measles can spread to others easily. Call your GP surgery before you go in. They may suggest talking over the phone.
'You can also call 111 or get help from 111 online.'
Heat rash is common during hot weather. It is uncomfortable, but usually harmless. It usually gets better on its own after a few days. Here are some tips to help you check if you have heat rash – and advice on how to treat it. More info ➡️ https://t.co/fyPl8UfYgB pic.twitter.com/3pzQIHx9Ic
— NHS (@NHSuk) June 21, 2025
You should call 999 or go to A&E if you or your child has measles and:
have a seizure (fit)
severe difficulty breathing – you're gasping, choking or not able to get words out (babies may make grunting noises or their stomach may suck under their ribcage)
are unable to stay awake – cannot keep their eyes open for more than a few seconds
suddenly become confused – your child may be very unsettled, behaving differently, or crying non-stop
your child is limp, floppy or not responding normally – their head may fall to the side, backwards or forwards, or they may find it difficult to lift their head and focus on your face
a rash that does not fade when you press a glass against it
a stiff neck or find light uncomfortable or painful
Measles will spread when a person who is infected coughs, sneezes or breathes.
The NHS said: 'You're infectious from when you first have symptoms (around 4 days before the rash appears) until 4 days after you get the rash.'
Recommended reading:
Should I take Vitamin D in the summer? What health experts advise
TV doctor highlights the importance of incoporating exercise in your daily life
Worst day of the year' for hay fever as pollen count tops 'very high' across UK
If you have measles, it's advised that you wash your hands often using soap and warm water, use tissues to cough and sneeze into and throw them away in the bin when finished with them.
It's important that you avoid sharing cutlery, cups, towels, clothes and bedding.
You can find out more about measles via the NHS website, linked above.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Market Surges Amid Rising Liver Disease and Cancer Prevalence
Market Surges Amid Rising Liver Disease and Cancer Prevalence

Yahoo

time35 minutes ago

  • Yahoo

Market Surges Amid Rising Liver Disease and Cancer Prevalence

The global ascites market is experiencing significant growth, driven by the rising prevalence of liver diseases, cancers, and other risk factors like alcohol consumption and hepatitis infections. Key advancements in diagnostic technologies, such as ultrasound and CT scans, are enhancing early detection and treatment options. Despite growth, challenges like high treatment costs and potential side effects hinder market expansion, particularly in developing regions. Leading companies, including Ocelot Bio and Regeneron Pharmaceuticals, are innovating to improve treatment efficacy. With increasing demand in emerging markets and an aging population, the ascites market is set for sustained growth. Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "Ascites Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ascites market is witnessing substantial growth, driven by a range of key factors. One of the primary drivers for the ascites market is the rising prevalence of liver diseases, particularly cirrhosis, as well as various forms of cancer, such as liver, ovarian, and pancreatic cancer. As these diseases are among the leading causes of ascites, their increasing incidence globally is driving the demand for diagnostic tools and treatment options. The global rise in lifestyle diseases, alcohol consumption, and hepatitis infections has contributed to this increase, which in turn propels the growth of the ascites market. As the ascites market continues to evolve, several emerging trends are expected to significantly influence its future trajectory. The aging global population is another significant factor driving the ascites market. Older adults are more prone to liver diseases, heart failure, and cancer, all of which are major risk factors for ascites. As the number of elderly individuals increases, the prevalence of ascites is expected to rise, further driving the demand for effective treatments and management strategies. Leading players in the global ascites market, such as Ocelot Bio, Regeneron Pharmaceuticals, and BioVie Inc., are continuously focusing on several strategies to maintain their competitive edge and drive growth. These strategies include continuous technological innovation, such as the development of more advanced and efficient treatment options, mapping systems, and imaging technologies. These companies aim to enhance the safety and efficacy of ascites treatment competitive landscape of the global ascites market is diverse, with numerous players across different regions offering a wide range of products. Regional players and local manufacturers are expected to play an important role in the market's growth, especially as demand increases in emerging markets such as Asia-Pacific and Latin America. As consumer preferences shift towards more discreet, comfortable, and affordable solutions, the ascites market will continue to evolve, fostering new opportunities for both established and emerging the development and improvement of diagnostic technologies, including imaging techniques like ultrasound, CT scans, and the use of paracentesis for fluid analysis, are major drivers for the ascites market. Early detection and accurate diagnosis allow for timely intervention, improving treatment outcomes. The availability of non-invasive and highly sensitive diagnostic tests increases the likelihood of diagnosing ascites in its early stages, expanding the demand for related treatment and management the positive growth trajectory, several challenges continue to impact the global ascites market. One of the primary challenges is the high cost of treatments, particularly for advanced interventions such as liver transplants, chemotherapy, and some novel drug therapies. These costs can be a significant barrier to access, especially in developing regions where healthcare infrastructure may be limited, and insurance coverage for expensive treatments may not be available. This high cost can restrict the market growth, as many patients may not be able to afford the necessary side effects and complications of treatment further restrict the market growth. Several treatments for ascites, including diuretics and paracentesis, can lead to complications or side effects, such as electrolyte imbalances, infections, or low blood pressure. These potential risks may deter patients from seeking treatment or adhering to prescribed regimens, thus limiting the overall demand for these interventions. Additionally, the invasive nature of some treatments, such as the need for repeated paracentesis, can be uncomfortable for patients and may result in decreased willingness to pursue these conclusion, the global ascites market is expected to see steady growth, driven by the increasing prevalence of underlying conditions such as liver diseases and cancers, as well as advancements in diagnostic and therapeutic options. Continued research and innovation in targeted treatments, along with a growing focus on early detection, will be key to improving patient outcomes and reducing the burden of ascites on healthcare systems. As stakeholders, including pharmaceutical companies, healthcare providers, and researchers, continue to work toward better management strategies, the market will evolve to offer more effective solutions, ultimately enhancing the quality of life for patients and addressing the ongoing challenges posed by this Topics Covered: 1. Global Ascites Markets: Industry Outlook1.1 Introduction1.2 Market Trends1.3 Regulatory Framework1.4 Epidemiology of Ascites1.5 Clinical Trial Analysis1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Challenges1.6.4 Market Opportunities2. Global Ascites Market, by Region, $Million, 2023-20352.1 North America2.1.1 Key Findings2.1.2 Market Dynamics2.1.3 Market Sizing and Forecast2.1.3.1 North America Ascites Market, by Country2.1.3.1.1 U.S.2.2 Europe2.2.1 Key Findings2.2.2 Market Dynamics2.2.3 Market Sizing and Forecast2.2.3.1 Europe Ascites Market, by Country2.2.3.1.1 Germany2.2.3.1.2 U.K.2.2.3.1.3 France2.2.3.1.4 Italy2.2.3.1.5 Spain2.3 Asia Pacific2.3.1 Key Findings2.3.2 Market Dynamics2.3.3 Market Sizing and Forecast2.3.3.1 Asia Pacific Ascites Market, by Country2.3.3.1.1 Japan3. Global Ascites Market: Competitive Landscape and Company Profiles3.1 Key Development and Strategies3.1.1 Mergers and Acquisitions3.1.2 Synergistic Activities3.1.3 Business Expansions and Funding3.1.4 Product Launches and Approvals3.1.5 Other Activities3.2 Company Profiles3.2.1 Ocelot Bio3.2.1.1 Overview3.2.1.2 Top Products / Product Portfolio3.2.1.3 Target Customers/End-Users3.2.1.4 Key Personnel3.2.1.5 Analyst View3.2.2 PharmaIN3.2.3 Grifols Therapeutics LLC.3.2.4 Regeneron Pharmaceuticals.3.2.5 BioVie Inc4. Research Methodology For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Market to Reach $14.34 Billion by 2034, Driven by Innovative R&D, Strategic Collaborations, and Drug Formulation Advancements
Market to Reach $14.34 Billion by 2034, Driven by Innovative R&D, Strategic Collaborations, and Drug Formulation Advancements

Yahoo

timean hour ago

  • Yahoo

Market to Reach $14.34 Billion by 2034, Driven by Innovative R&D, Strategic Collaborations, and Drug Formulation Advancements

The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by rising diabetes and obesity rates, innovative drug formulations, and supportive healthcare policies, the market is expanding. Key players include Eli Lilly, Sanofi, and Novo Nordisk. Challenges involve high costs and regulatory complexities. Opportunities lie in obesity treatment expansion and advanced drug delivery systems. European Glucagon-like Peptide-1 (GLP-1) Agonists Market Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034" has been added to offering. The Europe glucagon-like peptide-1 (GLP-1) agonists market is projected to witness significant growth, fueled primarily by an increased prevalence of type 2 diabetes and obesity. Originally valued at USD 7.09 billion in 2024, the market is estimated to expand at a compound annual growth rate (CAGR) of 17.30%, expecting a valuation of USD 14.34 billion by 2034. The competitive landscape features major pharmaceutical firms like Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, and others focused on innovative R&D, strategic collaborations, and drug formulation advancements. These companies aim to enhance market presence through mergers, acquisitions, and partnerships that promote access and compliance, ensuring sustained growth in the Europe's GLP-1 agonists market. The market's expansion is propelled by the increasing incidence of diabetes and obesity, augmented by sedentary lifestyles and poor dietary choices. GLP-1 agonists, as incretin-based therapies, are preferred for their efficacy in controlling blood sugar levels and facilitating weight loss, crucial aspects in managing diabetes and obesity. The growth trajectory is supported by rising healthcare expenditure, a burgeoning elderly demographic, advancements in drug delivery, and a robust regulatory framework favoring novel therapeutic adoption. Key Attributes: Report Attribute Details No. of Pages 300 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $7.09 Billion Forecasted Market Value (USD) by 2034 $14.34 Billion Compound Annual Growth Rate 7.3% Regions Covered Europe Market Drivers A surge in type 2 diabetes and obesity cases. Favorable government initiatives and reimbursement policies bolstering access to innovative treatments. Improved drug formulations like once-weekly injectables and oral options enhancing patient compliance. A growing trend towards combination therapies integrating GLP-1 agonists for optimized results. Market Challenges High costs of GLP-1 therapies affecting widespread accessibility. Potential side effects that could hinder patient adherence. Regulatory complexities delaying new therapy commercializations. Future Opportunities Expanding applications in obesity treatment beyond diabetes management. Innovative drug delivery system developments heightening market penetration. Strategic R&D investments for next-gen GLP-1 therapies with enhanced efficacy. Europe GLP-1 Agonists Market Trends The shift towards long-acting GLP-1 formulations like once-weekly injections elevating patient compliance. The increasing use of GLP-1 agonists in obesity management, supported by regulatory endorsements. Clinical validation of cardiovascular benefits driving GLP-1 adoption among patients at cardiovascular risk. Policymaker efforts in expanding healthcare coverage improving treatment accessibility. The development of multi-target GLP-1 therapies promises superior management of diabetes and weight issues. Strategic collaborations in biosimilar production broadening market access and affordability. Market Segmentation By Drugs: Key drugs include dulaglutide, exenatide, liraglutide, tirzepatide, lixisenatide, and semaglutide. By Application: The applications span type 2 diabetes mellitus and obesity treatment. By Route of Administration: Dominated by parenteral routes, the market is gradually seeing a rise in oral solution adoption. By End User: Primary users are hospitals, specialty clinics, academic research sites, with home care settings gaining traction. By Distribution Channel: Hospital pharmacies prevail, while retail and online pharmacies steadily gain ground. By Region: The United Kingdom, Germany, France, and Italy emerge as principal markets, bolstered by strong infrastructure and supportive policies. Companies Featured Eli Lilly and Company Sanofi Novo Nordisk A/S AstraZeneca plc For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment European Glucagon-like Peptide-1 (GLP-1) Agonists Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio

Epstein-Barr Is More Dangerous Than You Think
Epstein-Barr Is More Dangerous Than You Think

Bloomberg

timean hour ago

  • Bloomberg

Epstein-Barr Is More Dangerous Than You Think

Hi it's Karoline in Singapore, where one in four people will get cancer in their lifetime. A recent study found a common virus could be more powerful in causing cancers than previously thought. More on that in a moment, but first ... The Epstein-Barr virus is one of the most common human viruses, with more than 90% of people in the world being infected at some point of their lives. It's spread by saliva and causes mononucleosis, known as the 'kissing disease.' Though EBV generally causes mild flu-like symptoms, it has been linked to immune dysfunctions, lymphomas and nose and stomach cancers.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store